{
  "id": 15791169,
  "title": "OmniAb at LD Micro main event: royalties, scale and patience",
  "url": "https://urgent.news/2026/10/20/omniab-at-ld-micro-main-event-royalties-scale-and-patience",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-20T19:38:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/omniab-at-ld-micro-main-event-royalties-scale-and-patience-93CH-4960912"
  },
  "original_language": "en",
  "account": "OmniAb, at the LD Micro 20th Annual Main Event Conference on October 20, 2026, highlighted its antibody discovery platform as a long-term royalty generator. The company, which partners with 110 entities including eight of the top 10 global pharmaceutical companies, reported $52 million in cash and full-year revenue expectations of $32 million to $36 million. OmniAb's average royalty rate is 3.4%, with a total milestone potential of over $3 billion. The company's strategy emphasizes scale and diversification, and it is approaching cash break-even. Its new xPloration instrument business, aimed at a $500 million market, is also a growth driver. Despite modest royalty revenue, management anticipates growth as more partner programs reach commercialization.",
  "summary": null,
  "key_points": [
    "OmniAb showcased antibody discovery platform as long-term royalty generator at LD Micro conference.",
    "OmniAb's strategy focuses on scale, diversification, and approaching cash break-even."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}